Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 4/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832636 | 0.82 | TOP2A (0.51) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL1039242 | 0.82 | SMN1; SMN2 (0.55) | LMNASMN1; SMN2S1PR2NPSR1RPS6KB1 | |
| SCHEMBL29853721 | 0.79 | PDE5A (0.53) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL30808243 | 0.77 | EGFR (0.59) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL9609099 | 0.77 | RPS6KB1 (0.52) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL20434213 | 0.77 | HTR1A (0.87) | HTR1AADRA1DADRA1AADRA1BSMN1; SMN2 | |
| SCHEMBL18180893 | 0.76 | HTR1A (0.90) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL9206939 | 0.73 | EGFR (0.66) | EGFRLMNASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL11254575 | 0.73 | LDHA (0.67) | EGFRLMNASMN1; SMN2S1PR2NPSR1 | |
| SCHEMBL9214074 | 0.72 | EGFR (0.64) | EGFRLMNASMN1; SMN2AURKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR1A 118/4885ADRA1D 379/4885ADRA1A 512/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR1A 118/4885ADRA1D 379/4885ADRA1A 512/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR1A 93/4885ADRA1D 306/4885ADRA1A 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.